New drug discovery in the postgenomic era: from genomics to proteomics.
We have entered an exciting new era in which the nearly completed mapping of the human genome is now leading to the ability to characterize the human proteome, thereby expanding the horizon for new drug development by 3 orders of magnitude. Figuring out which proteins are involved in which disorders and in which individuals with any given disorder holds the promise of highly individualized therapeutics in the not so distant future.
Stahl
S M
SM
Neuroscience Education Institute in San Diego and the Department of Psychiatry at the University of California San Diego, USA.
D004345:Drug Industry / Q000379:methods*; D016678:Genome; D023281:Genomics / Q000379:methods*; D016045:Human Genome Project; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D020543:Proteome / Q000187:drug effects / Q000502:physiology*; D011619:Psychotropic Drugs / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use
D020543:Proteome; D011619:Psychotropic Drugs